|Day Low/High||7.81 / 8.42|
|52 Wk Low/High||5.21 / 22.20|
Investors in Advaxis, Inc. saw new options become available this week, for the December 16th expiration.
Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc.
New drugs give small-cap companies opportunity to expand markets and revenues.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach